New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
10:28 EDTZBRA, VRTX, VSTM, TFM, KPTI, ZINC, HOS, EBKDY, BRKR, BECNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Market Perform from Outperform at William Blair... Bruker (BRKR) downgraded to Neutral from Buy at ISI Group... Erste Group Bank (EBKDY) downgraded to Hold from Buy at Deutsche Bank... Hornbeck Offshore (HOS) downgraded to Equal Weight from Overweight at Stephens... Horsehead Holding (ZINC) downgraded to Market Perform at FBR Capital... Karyopharm (KPTI) downgraded to Perform from Outperform at Oppenheimer... The Fresh Market (TFM) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Perform from Outperform at Oppenheimer... Vertex (VRTX) downgraded to Perform from Outperform at Oppenheimer... Zebra Technologies (ZBRA) downgraded to In-Line from Outperform at Imperial Capital.
Check below for free stories on BECN;BRKR;EBKDY;HOS;ZINC;KPTI;TFM;VSTM;VRTX;ZBRA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
13:39 EDTBRKRThermo Fisher Q2 results bode well for PerkinElmer, Bruker, says Mizuho
Subscribe for More Information
12:16 EDTBRKRBruker says profitability to improve once CAM restructuring plan implemented
Bruker approved a plan to divest certain assets and implement a restructuring program in the Chemical & Applied Markets, CAM, division within the Bruker CALID Group. These divestment and restructuring actions are expected to result in a reduction of CAMís employee headcount by approximately 200 to 250 people and are expected to lead to CAM-related restructuring and other one-time charges of between $35M and $40M, of which $10M to $13M are expected to result in future cash charges for employee separation and facility exit costs, and $25M to $27M are estimated for inventory write-downs and asset impairments. The restructuring charges are expected to be incurred in the 2H14 and 1H15. Proceeds from potential divestitures cannot be estimated at this time. The company currently anticipates that the annual run-rate revenues for the CAM products and services will be reduced by approximately $50M-$70M, and profitability is expected to be improved by $15M to $20M annually, once the Plan is fully implemented. The company expects to provide further details on its CAM restructuring plans and financial outlook for 2014 on its Q214 earnings conference call scheduled for August 6. Additionally, as the Plan is implemented, management will continue to evaluate the estimated costs associated with the Plan and may revise its estimates of such costs and the related accounting charges.
12:09 EDTBRKRBruker to impliment restructuring program in CAM division
Subscribe for More Information
09:11 EDTHOSHornbeck Offshore downgraded to Accumulate from Buy at Tudor Pickering
Subscribe for More Information
July 20, 2014
12:21 EDTZINCHorsehead Holding has 40% upside, Barron's says
Subscribe for More Information
July 17, 2014
10:00 EDTTFMOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:22 EDTTFMThe Fresh Market initiated with an Underperform at Credit Suisse
Subscribe for More Information
06:20 EDTBRKRBruker initiated with a Buy at Citigroup
Subscribe for More Information
July 15, 2014
10:00 EDTTFMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:33 EDTTFMThe Fresh Market upgraded to Buy from Neutral at Northcoast
July 10, 2014
16:09 EDTVSTMVerastem says lead cancer stem cell inhibitor VS-6063 continues to show promise
Verastem hosted its annual Research and Development Day, at which it reports it said, "We continue to see promising clinical signals from the VS-6063 program. An additional partial response has been reported since our interim report at ASCO on the combination of VS-6063 and weekly paclitaxel in twenty-two patients with ovarian cancer. To date, best clinical response of at least stable disease has been observed in 14 of the 22 patients. This comprises two complete responses, three partial responses and nine patients with stable disease, including four patients whose disease has been stable for 6 months or longer. Eight patients continue on study drug. Based on this encouraging activity, we are planning a controlled Phase 2 study in patients with platinum resistant ovarian cancer.Ē The company also noted that it has made "significant progress in the past 12 months and have continued to further scientific understanding with all of our product candidates." Encouraged by these initial signs of clinical activity, the company reported it is adding additional studies to further test its hypothesis that the targeting of cancer stem cells may enable a more durable clinical response.
08:02 EDTVRTXVertex announces retirement of Chief Scientific Officer Mueller
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use